Morphotek
21
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
38.1%
8 terminated/withdrawn out of 21 trials
61.9%
-24.6% vs industry average
5%
1 trials in Phase 3/4
85%
11 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (21)
Dose Escalation Study MORAb-066 Targeting Tissue Factor (TF)-Expressing Malignancies Including Breast, Pancreatic, Colorectal, NSCLC
Role: lead
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
Role: lead
An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Role: lead
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
Role: lead
An Open Label Extension Study of the Efficacy of MORAb-003
Role: lead
A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung
Role: lead
Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM)
Role: lead
Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation
Role: lead
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer
Role: lead
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Role: lead
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
Role: lead
Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects
Role: lead
Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy
Role: lead
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
Role: lead
Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma
Role: lead
Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer
Role: lead
A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
Role: lead
A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma
Role: lead
A Study of of MORAb-004 in Subjects With Solid Tumors
Role: lead
Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer
Role: lead